Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul;131(7):843-50.
doi: 10.1001/jamaophthalmol.2013.4412.

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4

Age-Related Eye Disease Study 2 (AREDS2) Research Group  1 ; Emily Y Chew, John Paul SanGiovanni, Frederick L Ferris, Wai T Wong, Elvira Agron, Traci E Clemons, Robert Sperduto, Ronald Danis, Suresh R Chandra, Barbara A Blodi, Amitha Domalpally, Michael J Elman, Andrew N Antoszyk, Alan J Ruby, David Orth, Susan B Bressler, Gary E Fish, George B Hubbard, Michael L Klein, Thomas R Friberg, Philip J Rosenfeld, Cynthia A Toth, Paul Bernstein
Collaborators, Affiliations
Randomized Controlled Trial

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4

Age-Related Eye Disease Study 2 (AREDS2) Research Group et al. JAMA Ophthalmol. 2013 Jul.

Abstract

Importance: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020.

Objective: To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery.

Design, setting, and patients: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration.

Interventions: Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration.

Main outcomes and measures: Cataract surgery was documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery.

Results: A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95% CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95% CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).

Conclusions and relevance: Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.

Trial registration: clinicaltrials.gov Identifier: NCT00345176.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.
Flow Diagram of Participants in the Age-Related Eye Disease Study 2 of Lutein/Zeaxanthin Treatment for Age-Related Cataract DHA indicates docosahexaenoic acid; EPA, eicosapentaenoic acid.
Figure 2.
Figure 2.
Progression to Cataract Surgery in Age-Related Eye Disease Study 2 Participants by Treatment (Lutein/Zeaxanthin vs No Lutein/Zeaxanthin)
Figure 3.
Figure 3.
Effect of Lutein/Zeaxanthin Supplementation on the Progression of Cataract Stratified by Dietary Intake of Lutein/Zeaxanthin
Figure 4.
Figure 4.
Effect of Lutein/Zeaxanthin Supplementation on Moderate Vision Loss (3 or More Lines) From Baseline Stratified by Dietary Intake of Lutein/Zeaxanthin IQR indicates interquartile range.
See this image and copyright information in PMC

References

    1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11(2):67–115. - PubMed
    1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851. - PMC - PubMed
    1. Congdon N, O’Colmain B, Klaver CC, et al.; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–485. - PubMed
    1. Congdon N, Vingerling JR, Klein BE, et al.; Eye Diseases Prevalence Research Group. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122(4):487–494. - PubMed
    1. Leske MC, Chylack LT Jr, Wu SY. The Lens Opacities Case-Control Study: risk factors for cataract. Arch Ophthalmol. 1991;109(2):244–251. - PubMed

Publication types

MeSH terms

Associated data